Scancell-Neuphoria merger bets $79M on iSCIB1+ beating an approved TIL therapy in post-checkpoint melanoma, if Phase 3 confirms the 77% PFS signal

Neuphoria Therapeutics is a clinical-stage company developing an immunotherapy for advanced melanoma that has not yet been approved, competing against an existing approved cell therapy in patients who have failed earlier cancer treatments.

A Scancell-Neuphoria all-share merger, funded to 2029, consolidates around iSCIB1+, an active immunotherapy showing 77% progression-free survival at 22 months in advanced melanoma patients who have failed checkpoint inhibitors. The program competes directly against Iovance's approved autologous TIL therapy lifileucel in the same post-anti-PD-1 population, and the thesis resolves on whether Phase 3 confirms that PFS signal with a survival benefit. The Merck-partnered small molecule failure in Alzheimer's and the earlier BNC-210 Phase 3 miss in social anxiety disorder have stripped the company to a single unproven registrational bet.